North Stawell Minerals (ASX:NSM) Begins Diamond Drilling at Darlington
North Stawell Minerals (ASX:NSM) initiates diamond drilling at Darlington Project, advancing exploration in Victoria’s Stawell Gold Corridor.
Tag: Investor Relations
Industrial Minerals Limited (ASX:IND) Addresses ASX Price Query
Industrial Minerals Limited (ASX:IND) responds to ASX’s query on recent trading activity, citing increased demand for High Purity Quartz and ongoing project developments.
Norwest Minerals Limited (ASX:NWM) Announces West Arunta Exploration Results
Norwest Minerals (ASX:NWM) reports significant titanium and silver-base metal drilling results from West Arunta project, indicating strong growth potential.
Race Oncology (ASX:RAC) Executes $8.6m Contract for Phase 1 RC220 Trial
Race Oncology (ASX:RAC) secures an $8.6m contract with George Clinical to advance Phase 1 trials of RC220 in solid tumour patients.
AusQuest Limited (ASX:AQD) Initiates Stage 2 Drilling at Cangallo Project
AusQuest Limited (ASX:AQD) initiates Stage 2 drilling at its Cangallo Project in Peru, aiming to expand its copper-gold discovery.
KALiNA Power Limited (ASX:KPO) Announces Pro-Rata Rights Issue
KALiNA Power Limited (ASX:KPO) launches a pro-rata rights issue to raise up to $1.04 million for expanding its clean-tech initiatives.
Oceania Healthcare (ASX:OCA) Reports FY25 Market Update and Refinancing
Oceania Healthcare (ASX:OCA) reports increased sales, successful $500m debt refinancing, and strategic business optimisations for FY25.
Guzman y Gomez Limited (ASX:GYG) Responds to ASX Compliance Inquiry on Half-Year Earnings
Guzman y Gomez Limited (ASX:GYG) confirms its half-year earnings aligned with market expectations in response to ASX compliance inquiry.
Oceania Healthcare (ASX:OCA) Announces Refinance and Market Update
Oceania Healthcare (ASX:OCA) completes debt refinancing and reports a 29% increase in new sales volumes in its latest market update.
Invion Limited (ASX:IVX) Completes $2M Share Placement to Advance Clinical Programs
Invion Limited (ASX:IVX) successfully raises $2M through a share placement to fund its Phase I/II cancer clinical trials.